Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

INTRODUCTION: Despite the high prevalence of non-alcoholic fatty liver disease (NAFLD) and its associated co-morbidities, no efficient treatment in a high percentage of individuals is available. Beneficial effects of sodium–glucose co-transporter 2 inhibitors on fatty liver have been investigated in...

Descripción completa

Detalles Bibliográficos
Autores principales: Taheri, Hoda, Malek, Mojtaba, Ismail-Beigi, Faramarz, Zamani, Farhad, Sohrabi, Masoudreza, Reza babaei, Mohammad, Khamseh, Mohammad E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547956/
https://www.ncbi.nlm.nih.gov/pubmed/32975679
http://dx.doi.org/10.1007/s12325-020-01498-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547956/
https://www.ncbi.nlm.nih.gov/pubmed/32975679
http://dx.doi.org/10.1007/s12325-020-01498-5

Ejemplares similares